Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"Reversing Oxinflammation Associated with Glycative Stress and Formation of Advanced Glycation End Products with a Dietary Supplement Containing Rosemary Extract.","authors":"Anna Guiotto, Alessandra Pecorelli, Zoe Diana Draelos, Audrey Gueniche, Margarita Yatskayer, Diane B Nelson","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Skin aging is accelerated by glycative stress, which promotes the accumulation of advanced glycation end products (AGEs) and impairs the extracellular matrix. A randomized, double-blinded, placebo-controlled trial evaluated a dietary supplement containing rosemary extract (BioR), demonstrating tissular and visible improvements in skin quality. The data reported herein evaluated markers associated with glycative stress and AGEs from skin biopsies and tape strips obtained following dietary supplement use.</p><p><strong>Methods: </strong>Female participants (N=104), aged 40 to 65 years, with moderate-to-severe skin dullness and roughness/texture, and mild-to-moderate erythema, pore size, and uneven pigmentation were randomized to BioR (n=52) or placebo ([PLB] n=52). Capsules were taken with food over 12 weeks. Subjects (n=16, BioR; n=16, PLB) underwent 3mm punch biopsies (volar upper arm) and tape stripping (16 tape strips, each; volar forearm) at baseline and 12 weeks for analysis of 4-hydroxynonenal protein adducts (4HNE [oxidative stress marker]) and AGEs.</p><p><strong>Results: </strong>Immunohistochemistry and ELISA revealed that levels of 4HNE protein adducts were significantly decreased from baseline in the BioR versus PLB group (<i>p</i><0.005; biopsies) and significantly decreased from baseline in the BioR group alone (<i>p</i><0.05; tape strips) at 12 weeks. Significant reductions in AGEs occurred in the BioR versus PLB group (<i>p</i><0.005; biopsies) at 12 weeks. No significant changes from baseline occurred in 4HNE protein adduct levels or AGEs in the PLB group.</p><p><strong>Conclusion: </strong>After 12 weeks, a dietary supplement containing rosemary extract led to significant reductions in a marker associated with oxidative stress, a component of glycation, and AGEs versus placebo in skin in addition to visible improvements in skin quality.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"34-38"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biostimulatory Fillers to Treat Post-liposuction Skin Irregularities.","authors":"Stefania Guida, Ilaria Proietti, Claudio Conforti, Carmen Cantisani, Nicola Zerbinati, Giovanni Pellacani, Hassan Galadari","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Treatment of post-liposuction skin irregularities (PLSI), a complication of liposuction, can be challenging.</p><p><strong>Objective: </strong>Considering the increasing request of treatment of PLSI, the aim of this study is to evaluate the efficacy and safety of CaHA diluted/hyperdiluted to PLSI.</p><p><strong>Methods: </strong>A retrospective study on a total of eight PLSI areas in six women treated with CaHA diluted/hyperdiluted was performed. Efficacy was estimated on pictures of affected areas collected before and four months after treatment, according to the recently validated PLSI scale and Student's t-test for paired samples was performed to analyze data. Eventual adverse events were used to evaluate safety.</p><p><strong>Results: </strong>Our results showed a statistically significant improvement of number and depth of depressions and a trend toward reduction of skin laxity.</p><p><strong>Conclusion: </strong>This study reported the efficacy and safety of CaHA diluted/hyperdiluted for PLSI treatment. Larger studies are encouraged to support the results of this pilot study.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"39-41"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Strontium Cream in Alleviating Pruritus in Hidradenitis Suppurativa.","authors":"Rubi Walker, Brindley Brooks, Steven Daveluy","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition with limited treatment options and a significant impact on quality of life. This prospective, open-label, real-world study aimed to evaluate the efficacy of strontium cream in alleviating pruritus in HS.</p><p><strong>Methods: </strong>Fifty participants completed baseline and one-week post-intervention surveys. Pruritus was assessed using a numeric severity scale and a qualitative survey on overall itch reduction.</p><p><strong>Results: </strong>Statistical analysis revealed a significant reduction in itching symptoms post-intervention, with mean itch scores decreasing from 3.80±0.90 at baseline to 2.28±1.50 post-intervention (<i>p</i><0.001). Participant feedback also indicated overall satisfaction, with 84 percent of participants willing to recommend the cream to other HS patients.</p><p><strong>Limitations: </strong>The study relied on self-reported data, which introduces subjectivity, and the absence of a control group limits causal inference.</p><p><strong>Conclusion: </strong>Strontium cream demonstrates promise as a therapeutic option for managing pruritus in HS, warranting further research.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"12-14"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Psyche to Skin: A Call for Interdisciplinary Care in the Management of Psychodermatologic Conditions.","authors":"Mary D Sun, Brandon R Block, Simran Ohri, Timothy Rice","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Despite increasing academic discourse surrounding psychodermatology, few dermatologists or psychiatrists demonstrate a clear understanding of the field. Barriers to physician awareness are double-edged, stemming from both inadequate educational opportunities and patient non-disclosure of psychodermatologic symptoms during clinical encounters. It is crucial that medical practitioners, especially in the field of dermatology, become accustomed to recognizing, diagnosing, and treating psychocutaneous disorders, which disproportionately affect members of historically marginalized populations. In this commentary, we propose recommendations for pedagogic supplements to be implemented throughout medical, post-graduate, and post-residency education to build familiarity with this subdiscipline and confidence in managing its associated conditions. In particular, we endorse the integration of components of psychiatry education into dermatology residency training and current practice, as skin symptoms tend to be more openly disclosed than mental health struggles, so dermatologists are often the first physicians to encounter many of these conditions. We also advocate for interdisciplinary collaboration to bridge the gap between the uniformity of standard specialty training and the complexity of psychocutaneous disease.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"67-70"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Acne Scarring on Quality of Life, Willingness-to-pay, and Time Trade-off: A Cross-sectional Analysis.","authors":"Henriette De La Garza, Nicole Trepanowski, Rene Flores, Poom Visutjindaporn, Nicole Patzelt, Neelam A Vashi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>We sought to evaluate the impact of the presence of acne scarring in patients with acne vulgaris on quality of life as assessed by the Dermatology Life Quality Index (DLQI) and the Cardiff Acne Disability Index (CADI); disease severity using the Investigator's Global Assessment of Acne (IGA); and health utility measures including willingness-to-pay, time trade-off, time spent on concealment, and percent of income willing to exchange for resolution of disease.</p><p><strong>Methods: </strong>We conducted a cross-sectional, single-institution survey.</p><p><strong>Results: </strong>In total, 94 patients with acne vulgaris participated, of which 53.2 percent had acne scarring and 46.8 percent did not. The presence of acne scarring was associated with higher DLQI, CADI, and IGA scores. Utility measures including willingness-to-pay, time trade-off, concealment time, and percent of income willing to exchange for resolution of disease were similar for participants with and without scarring. For participants with and without scarring, a greater impairment of quality of life as assessed by the DLQI was positively correlated with WTP25, percent of monthly income, IGA, and the CADI.</p><p><strong>Limitations: </strong>As the study design was single-site and cross-sectional, and therefore results may not be generalizable.</p><p><strong>Conclusion: </strong>The presence of acne scarring significantly impacts quality of life. A greater impairment of quality of life in patients with acne vulgaris correlates positively with severity of acne and some measures of health economics. Interventions to minimize or prevent acne scarring may reduce psychosocial burden of disease.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"71-73"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of Glucagon-like Peptide-1 in Dermatology.","authors":"Willmar Patino, Amanda Thomas, Sanjana Jain, James Q Del Rosso, Naiem T Issa","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Glucagon-like peptide-1 (GLP-1) is a hormone produced in response to meal intake by endocrine intestinal cells. GLP-1 binds to its receptors which are expressed on various cells throughout the body. GLP-1 receptors (GLP-1R) have become a target for the treatment of diabetes mellitus and weight loss, and GLP-1 receptor agonist (GLP-1RA) use has become more common among patients. In addition to the anti-hyperglycemic effects, recent studies have exhibited anti-inflammatory effects of GLP-1RAs. Current research surrounding GLP-1Rs and GLP-1R agonism in dermatology is limited. This review aims to describe the current knowledge of GLP-1Rs and GLP-1RA use in dermatology and suggest future directions.</p><p><strong>Methods: </strong>A literature search focused on GLP-1RAs and their effect on cutaneous disease processes was performed across various databases. The databases were searched through May 2024.</p><p><strong>Results: </strong>The use of GLP-1RAs have shown promising anti-inflammatory effects and improvement in wound healing, psoriasis, and hidradenitis suppurativa. Several cutaneous adverse reactions to GLP-1RAs were also identified with injection site pruritus, erythema, and rash being the most commonly reported.</p><p><strong>Limitations: </strong>Current literature is limited to case reports and small-scale studies.</p><p><strong>Conclusion: </strong>The literature suggests anti-inflammatory effects of GLP-1RAs may provide direct benefit in the treatment of dermatologic conditions independent of glucose control in addition to indirect improvement via modulation of blood glucose and weight loss. Further studies investigating the implications of GLP-1RA use and the possible therapeutic potential of GLP-1RAs in inflammatory skin conditions are warranted.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"42-50"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing Advanced Basal Cell Carcinoma: A Guide for the Dermatology Clinician.","authors":"Joshua Burshtein, Todd Schlesinger","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Basal cell carcinoma (BCC) is the most common form of skin cancer. Advanced BCCs include locally advanced BCCs (laBCCs), primary or recurrent tumors that are not amenable to surgery or radiation therapy, and metastatic BCCs (mBCCs). The management of advanced BCC has been revolutionized in recent years by the development of hedgehog inhibitors (HHIs) and immunotherapies (ie, PD-1 inhibitors). We aim to review the current literature on therapeutic options and outline treatment strategies to optimize care for patients with advanced BCC.</p><p><strong>Methods: </strong>A comprehensive literature search was completed using the keywords \"advanced basal cell carcinoma,\" \"treatment,\" \"hedgehog inhibitor,\" \"vismodegib,\" \"sonidegib,\" \"PD1-inhibitor,\" and \"cemiplimab.\" The authors reviewed all studies and included those which addressed the topic of the review.</p><p><strong>Results: </strong>Surgery or radiotherapy may not be an option for certain high-risk BCCs due to due to invasion into local tissue, location near anatomically sensitive areas, or metastasis. There is increasing evidence for the efficacy of HHIs, including vismodegib and sonidegib, as the first-line treatment for these advanced BCCs. Despite known efficacy, utility of HHIs can be limited by their adverse event profiles. If patients fail HHIs due to inefficacy or adverse effects, there is evidence for use of the PD-1 inhibitor cemiplimab.</p><p><strong>Limitations: </strong>This is a review article and is limited by the information available in the published literature. In addition, comparison between studies is limited as they utilized varying methodologies.</p><p><strong>Conclusion: </strong>Treatment of advanced BCCs can be complex and poses challenges for clinicians. HHIs are currently the first-line treatments for laBCC and mBCC, while cemiplimab can be used if patients do not respond to or are unable to tolerate HHIs, or for whom HHIs are not appropriate.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"21-27"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Single-center, Double-blinded, Randomized, Placebo-controlled Trial Evaluating the Safety and Efficacy of a Dietary Supplement Containing Rosemary Extract on Visible Facial Skin Quality.","authors":"Zoe Diana Draelos, Audrey Gueniche, Margarita Yatskayer, Diane B Nelson","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Glycative stress promotes the accumulation of advanced glycation end products (AGEs), impairing extracellular matrix proteins and accelerating skin aging. Rosemary extract has been shown to deglycate AGE crosslink proteins. The safety of a dietary supplement containing rosemary extract (BioR) and its efficacy on skin quality parameters was evaluated over 12 weeks.</p><p><strong>Methods: </strong>The randomized, double-blinded, placebo-controlled trial included female participants, aged 40 to 65 years, with moderate-to-severe skin dullness and roughness/texture, and mild-to-moderate erythema, pore size, and uneven pigmentation based on a six-point grading scale. Subjects were randomized to either BioR (n=52) or placebo ([PLB] n=52). The dosing schedule was as follows: from Weeks 1 to 4, two capsules three times daily; from Weeks 5 to 8, two capsules twice daily; from Weeks 9 to 12, one capsule twice daily. Capsules were taken with food. Investigator assessments occurred at baseline and Weeks 4, 8, and 12. Global skin quality (total sum of scores) and adverse events (AEs) were recorded over 12 weeks.</p><p><strong>Results: </strong>Mean age, severity and baseline demographics of subjects were similar across groups. Significant mean improvements in BioR versus PLB were observed in skin dullness (<i>p</i>=0.04), roughness/texture (<i>p</i>=0.001), erythema (<i>p</i>=0.05) and pore size (<i>p</i>=0.04) at Week 12. No significant differences occurred in uneven pigmentation. Significant mean improvements in global skin quality were demonstrated in BioR versus PLB at Weeks 8 (<i>p</i><0.0001) and 12 (<i>p</i>=0.002). One subject (BioR) discontinued at Week 4 due to possibly related, moderate gastrointestinal upset.</p><p><strong>Conclusion: </strong>Following 12 weeks of use, a dietary supplement containing rosemary extract and its natural cofactors led to significant mean visible improvements compared to placebo in skin dullness, roughness/texture, erythema, and pore size, and was well tolerated.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"28-33"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Overview of Atopic Dermatitis Disease Burden, Pathogenesis, and the Current Treatment Landscape: Recommendations for Appropriate Utilization of Systemic Therapies.","authors":"George Martin, Lakshi Aldredge, Douglas DiRuggiero, Melodie Young, Eric Simpson","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To review the disease impact, immunopathogenesis, and treatment landscape of atopic dermatitis (AD), including recommendations for appropriate utilization of systemic treatments.</p><p><strong>Methods: </strong>A PubMed search for relevant articles on AD and the treatment landscape was conducted using the key words \"atopic dermatitis,\" \"biologic,\" \"therapeutic inertia,\" \"Janus kinase (JAK) inhibitor,\" and \"systemic treatment.\"</p><p><strong>Results: </strong>AD is a common, chronic inflammatory skin disease that can have a profound negative impact on quality of life. With recent advancements and approvals of systemic treatments, it is now possible to offer targeted therapy to patients with moderate-to-severe AD. When topical treatments are no longer sufficient for managing AD, recently published AD management guidelines recommend that providers consider/offer advanced systemic treatments.</p><p><strong>Limitations: </strong>More data are needed on the use of systemic treatments in special populations, including head-to-head comparisons of available systemic treatments in these populations.</p><p><strong>Conclusion: </strong>An increased awareness of the immunopathogenesis, diagnosis, and treatment landscape of AD is needed amongst healthcare providers (HCPs). Special consideration of diagnosis and treatment options should be given to certain populations, including patients of different ages, those who may be pregnant or become pregnant, are biologic-experienced, and/or have comorbidities. Of note, HCPs should be aware of the clinical presentation in patients with skin of color. Therapeutic inertia can prevent HCPs from intensifying treatment when needed, and HCPs should know when it is appropriate to offer systemic treatments, including biologics and JAK inhibitors.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"51-66"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Link Between Atopic Dermatitis and Eosinophilic Esophagitis.","authors":"Joanna Jaros, Kripa Ahuja, Peter Lio","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Eosinophilic esophagitis (EoE) and atopic dermatitis (AD) are two known and sometimes comorbid type 2 helper cell-mediated diseases. EoE shares clinical features, immunologic pathways, susceptibility loci, and risk with atopic conditions including food allergies (food allergies), asthma, allergic rhinitis (AR), and AD. These conditions share an impaired immunological response against a range of antigens or allergens, leading to CD4+ Th2 differentiation and overproduction of immunoglobulin E (IgE). The emerging coexistence of EoE and AD presents a compelling area of study. Both diseases manifest on stratified squamous epithelium along the skin-gut continuum and have overlapping treatment algorithms that include avoidance of triggers, topical steroids, and dupilumab. This narrative review highlights the clinical and immunologic nuances underlying these two conditions and sheds light on potential new research and therapeutic avenues.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 3","pages":"15-20"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}